



FOR IMMEDIATE RELEASE

Strong demand for eye care services lifts ISEC Healthcare Ltd.'s FY2018 performance

- Net profit rises 10% to S\$8.7 million on the back of increased revenue, which grew 9% to S\$40.4 million.
- Proposes final dividend of 0.78 Singapore cents per share and a special dividend of 0.98 Singapore cents per share, which together with the interim dividend of 0.78 Singapore cents per share, brings total dividend to 2.54 Singapore cents per share for FY2018.

| Financial Highlights (S\$ Million) | 3 months ended 31 Dec | | | 12 months ended 31 Dec | | |
|---|-----------------------|---------|---------------|------------------------|--------|---------------|
| | 4Q 2018 | 4Q 2017 | Change (%) | FY2018 | FY2017 | Change (%) |
| Revenue | 10.5 | 9.5 | 10 | 40.4 | 37.0 | 9 |
| Gross Profit | 5.1 | 4.5 | 12 | 19.5 | 17.5 | 11 |
| Gross Profit Margin (%) | 48.4% | 47.6% | 0.8 pt | 48.1% | 47.3% | 0.8 pt |
| Net profit | 2.4 | 2.1 | 17 | 8.7 | 7.9 | 10 |
| Profit attributable to owners of the parent | 2.3 | 2.1 | 10 | 8.4 | 7.9 | 6 |
| Earnings per share* | 0.45 | 0.41 | 10 | 1.63 | 1.53 | 7 |

*Based on the weighted average number of 517,095,669 ordinary shares in issue during and as at the end of the respective financial periods.

SINGAPORE, 26 February 2019 – ISEC Healthcare Ltd. (“ISEC” or together with its subsidiaries, the “Group”), an established regional provider of a comprehensive suite of medical eye care services with ambulatory surgical centres, has proposed a special dividend of 0.98 Singapore cents per share in addition to a final dividend of 0.78 Singapore cents per share in line with its strong performance for the 12 months ended 31 December 2018 (“FY2018”).

Together with the interim dividend of 0.78 Singapore cents per share, this brings the total dividend for FY2018 to 2.54 Singapore cents per share or approximately S\$13.1 million, which is approximately 151% of the Group’s net profit for FY2018. The final and special dividend is subject to shareholders’ approval at the upcoming annual general meeting in April 2019.



In FY2018, the Group generated a 10% year-on-year (“YOY”) increase in net profit to S\$8.7 million. The sterling bottomline performance was achieved on the back of increased revenue, which expanded 9% YOY to S\$40.4 million.

The Group attributed its results mainly to higher revenue from an increase in patient visits at its specialised eye-care centres in Malaysia and Singapore. In Malaysia, the Group’s revenue rose 11% from S\$28.0 million for the financial year ended 31 December 2017 (“FY2017”) to S\$31.0 million in FY2018, while its Singapore operations garnered a 5% increase in revenue to S\$9.4 million over the same period. Rising in tandem with the topline, gross profit came in 11% higher YOY at S\$19.5 million with gross profit margin also increasing 0.8 points to 48.1% in FY2018.

On a quarterly basis for the 3 months ended 31 December, the Group’s revenue and gross profit increased 10% YOY to S\$10.5 million and 12% YOY to S\$5.1 million respectively, while gross profit margin was 0.8 percentage points higher at 48.4%. This lifted net profit by 17% to S\$2.4 million for the three months ended 31 December 2018 (“4Q2018”).

Influenced by the strong full-year performance, the Group’s earnings per share rose 7% YOY to 1.63 Singapore cents per share in FY2018. As at 31 December 2018, the Group’s net asset value per share was 0.13 Singapore cents, while cash and cash equivalents stood at a healthy at S\$27.1 million with no borrowings.

Dr Wong Jun Shyan, ISEC Executive Director and Chief Executive Officer, said: *“FY2018 was a good year for ISEC with stronger bottomline performance from both our specialised eye care and general health services. Our clinics in our key markets of Singapore and Malaysia observed greater footfall with more patients seeking treatment. We are pleased to share our earnings with shareholders in view of the financial results.”*

“Looking ahead to the next 12 months, we believe the region’s ageing population as well as increasing awareness about the benefits of seeking early treatment for ophthalmology issues will continue to drive demand for the specialised services that we provide. We will continue to search for investment opportunities to strengthen our presence in our existing markets and to explore new markets such as China, Indonesia, Myanmar and Vietnam,” added **Dr Wong**.

In August 2018, ISEC announced the incorporation of ISEC Myanmar Company Limited (“ISEC Myanmar”) together with three other independent parties. The new entity will operate and administer ophthalmology centres and provide medical consultations and services in Myanmar and is expected to commence operations in the second quarter of 2019.

Also in August 2018, ISEC expanded its general medical services and aesthetic treatment services arm when its 100% owned subsidiary JL Medical (Bukit Batok) Pte. Ltd. acquired a 25% stake in I Medical & Aesthetics Pte. Ltd.. This investment is expected to bring new business opportunities in



the field of general medical consultations and aesthetics services in Singapore. In addition to diversifying the Group's revenue stream, the investment also offers the possibility of synergistic partnerships and cross-selling with the Group's existing business of specialist medical eye care services.

As the Group's Malaysia operations contribute more than half of the Group's total revenue, the revenue from Malaysia operations translated to Singapore Dollar will be impacted by foreign exchange movements as the presentation currency of the Group is in Singapore Dollar. We will continue to monitor the impact of the movement of the Malaysian Ringgit on the Singapore Dollar.

About ISEC Healthcare Ltd. ("ISEC" and together with its subsidiaries, the "Group")

Listed on the Catalist board of the Singapore Exchange Securities Trading Limited on 28 October 2014, ISEC is an established regional provider of a comprehensive suite of medical eye care services with ambulatory surgical centres.

In Malaysia, the Group operates medical eye care centres in Kuala Lumpur, Malacca, Penang and Sib. In Singapore, ISEC Eye Pte. Ltd. ("ISEC Eye") provides specialist medical ophthalmology services to Lee Hung Ming Eye Centre located in Singapore's Gleneagles Hospital.

In 2016, the Group expanded its healthcare services to include general medical services and aesthetic treatment services.

Issued on behalf of ISEC Healthcare Ltd by

August Consulting Pte Ltd

Tel: (65) 6733 8873 Fax: (65) 6733 9913

Wrisney Tan – wrisneytan@august.com.sg

Janice Ong – janiceong@august.com.sg

This announcement has been prepared by the Company and its contents have been reviewed by the sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).